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Abstract: Osteosarcoma (OS) is the most common primary bone malignancy and largely effects
adolescents and young adults, with 60% of patients under the age of 25. There are multiple cell
models of OS described in vitro that express the specific genetic alterations of the sarcoma. In
the work reported here, multiple mass spectrometry imaging (MSI) modalities were employed to
characterise two aggregated cellular models of OS models formed using the MG63 and SAOS-2 cell
lines. Phenotyping of the metabolite activity within the two OS aggregoid models was achieved
and a comparison of the metabolite data with OS human tissue samples revealed relevant fatty acid
and phospholipid markers. Although, annotations of these species require MS/MS analysis for
confident identification of the metabolites. From the putative assignments however, it was suggested
that the MG63 aggregoids are an aggressive tumour model that exhibited metastatic-like potential.
Alternatively, the SAOS-2 aggregoids are more mature osteoblast-like phenotype that expressed
characteristics of cellular differentiation and bone development. It was determined the two OS
aggregoid models shared similarities of metabolic behaviour with different regions of OS human
tissues, specifically of the higher metastatic grade.
Keywords: osteosarcoma; DESI; mass spectrometry imaging; LA-ICP-MS; metabolomics; imaging
mass cytometry
1. Introduction
Osteosarcoma (OS) is the most common primary bone malignancy and largely effects
adolescents and young adults, with 60% of patients under the age of 25. Bone sarcomas are
classified as a rare type of cancer with OS having an estimated incidence of approximately
7 in 100,000 persons, with 30,000 new cases a year [1]. Despite improvements in treatment
therapies over the recent years, the survival rate of bone sarcomas has remained unchanged
with <50% at 5 years [2]. The aggressive tumoral behaviour of OS has challenged the
development of an effective therapeutic treatment. Even with complete surgical resection
of the primary tumour, approximately 90% of OS patients develop metastasis such as of
the lung or breast [3]. Hence, there is still a great need for studying the molecular activity
within the sarcoma in order to understand the metastatic behaviour and improve treatment
therapies.
There are multiple cell models of OS described in vitro that express the specific genetic
alterations of the sarcoma. The most common OS cell lines include the epithelial-like cells,
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SAOS-2 and the fibroblastic-like cells, MG63, both with a deficiency mutation in the tumour
suppressor p53 gene. However, significant differences in the phenotypes of these cell lines
have contributed to inconsistent results across studies. The SAOS-2 cells express a mature
osteoblast phenotype with a high level of alkaline phosphatase (ALP) activity [4] a gene
associated with bone mineralisation. In contrast, the MG63 cell line represent the immature
osteoblast phenotype with low ALP activity and matrix differentiation potential [5].
With differences in phenotypes, the expression of endogenous molecules would also
be expected to vary, and thus impact the responses to treatment. Multiple previous studies
have characterised the OS cell lines by DNA profiling and the expression of proteins
using conventional methods, such as PCR analysis and immunostaining. For example,
the detection of metastatic-related OS gene expressions, such as PHLDA1 enabled the
categorisation of 18 OS cell lines from high to low metastatic potential, marking SAOS-2
and MG63 as relatively low metastatic cell lines [3]. In addition, heterogenous expressions
of ECM proteins such as collagen I and III, and MMP-9 were used to differentiated SAOS-2
cells from MG63 cells [6]. Untargeted liquid chromatography tandem mass spectrometry
(LC-MS/MS) approaches have also been employed in metabolomics studies of both OS cell
lines [7,8]. The limitations of these studies, however, is the characterisation of the OS cell
lines in 2D, which is not representative of in vivo behaviour.
Alternatively, three-dimensional (3D) cell cultures, such as tumour spheroids, offer
a biologically relevant model that can be used for cancer research and early-stage drug
development studies. The cellular complexity of 3D models mimics tumour microenvi-
ronment of proliferative, hypoxic, and necrotic regions through gradients of oxygen and
nutrients. By recapitulating the cell−cell interactions and the gene and protein expres-
sions of tumours in a way that 2D cultures cannot, 3D cultures are therefore a valuable
research tool to study realistic drug behaviour. For instance, significant changes in the
metabolite levels of lactate and alanine between 2D and 3D MG63 cultures were detected
by high resolution nuclear magnetic resonance (NMR) [9]. Additionally, alterations in the
proteome between monolayer and spheroid cultures of canine OS cells by differential gel
electrophoresis (DIGE) matrix-assisted laser desorption ionisation (MALDI)-MS has also
been reported [10]. However, according to the literature the characterisation of OS 3D
culture models has still been limited to profiling or immunostaining techniques, which
leads to loss of spatial information and/or requires target-specific analysis [10–12].
In order to understand the wide molecular activity that drives OS and captures the
heterogeneity of the tissue, a comprehensive analysis strategy is required. Mass spectrome-
try imaging (MSI) is a multiplex methodology that has the capability to map molecular
distributions within biological tissues via an unlabelled approach. The spatial localisation
of a molecule can determine the interplay of biological functions and interactions within
a tissue. This also enables a greater biological understanding of cellular phenotypes and
their structural organisation, in addition to the surrounding microenvironment. For exam-
ple, previously defined proliferative and apoptotic and necrotic regions within a SAOS-2
spheroid aggregate model has been determined by detecting heterogeneous distributions
of endogenous metabolites using MALDI-MSI [13]. Furthermore, we have previously
employed multimodal MSI techniques to demonstrate how obtaining a large amount of
molecular information with a complementary nature can enhance the understanding of
the biological processes within a tissue. The detection of metabolites, proteins and metals
determined the interplay between molecules and established key pathways that defined
a novel HCC827 lung adenocarcinoma ‘aggregoid’ model [14]. A similar approach could
therefore give a valuable insight into 3D tumour aggregoid models of OS, providing com-
prehensive information of biochemical pathways that influence the cancer pathogenesis. In
addition to this, a recent paper demonstrated the combination of oesophageal cancer multi-
cellular tumour spheroids (MCTS) and clinical tissue with MALDI-MSI as an approach to
determine the metabolic relevance of the models to in vivo [15]. With that in mind, detailed
molecular characterisation of in vitro OS models and clinical tissue would improve the
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understanding of cancer metabolism within the 3D cultures and highlight biomarkers of
patient outcome.
In the work reported here, multiple MSI modalities were employed to characterise
two novel OS aggregoid models, MG63 and SAOS-2, for the purposes of developing a
potential in vitro methodology for pre-clinical cancer research and drug development.
Firstly, the metabolic profiles of the models were determined by desorption electrospray
ionisation (DESI)-MSI and compared against the established tumour microenvironment of
the HCC827 lung adenocarcinoma aggregoid. An investigation into the relevance of the OS
aggregoid models with clinical OS patient samples was then conducted to determine the
similarities in the metabolite expressions that influenced tumour behaviour and potentially
detect metastatic-like activity. In addition, imaging mass cytometry (IMC) and laser
ablation inductively coupled plasma (LA-ICP)-MSI were utilised to further establish the
phenotypical characteristics of the tumour microenvironments of both aggregoid models




To determine the metabolic profiles of the two OS aggregoid models, a comparative
analysis was performed by employing DESI-MSI. In this study, the metabolic activity within
three biological replicates of the MG63 and SAOS-2 aggregoid models were determined.
Metabolite data of a HCC827 lung adenocarcinoma model were also included as a reference
to understand the phenotypes within the OS models.
Initially, the data were spatially segmented to determine phenotypical regions within
the aggregoid sections. From the segmentation analysis, differences of the phenotypical
regions in each model were observed (Figure 1). As reported previously [14], the segmented
image of an HCC827 aggregoid model comprised three regions: a distinctive inner core, an
annular zone and an outer region, which were also observable in the histological image.
The segmentation of the MG63 model showed a similar pattern, where a core, two annular
regions and a periphery were observable in the segmented MSI data. From the histology
however, the MG63 model differed from the HCC827 aggregoid in that the cells were
tightly compacted throughout the section and although some condensing of DNA was
observed, no significant apoptotic bodies were identified. This suggests that the core cluster
within the MG63 aggregoid does not necessarily correspond to an obvious region of cellular
stress due to hypoxia. Yet, the segmentation analysis was still able to identify changes in
metabolite activity affected by the lack of oxygen and nutrients towards the core of the
aggregoid.
The SAOS-2 model showed significantly different features to the HCC827 and MG63
models in the segmentation analysis (Figure 1). Although a core was identified, the
clustering pattern showed a lot of heterogeneity across the section, which was similar
in each SAOS-2 sample (n = 3). Examination of the histological data indicated that a lot
of fracturing was present. This has been noted across the SAOS-2 aggregoid samples
throughout the experimental work conducted and is potentially due to the nature of
culturing the SAOS-2 cell line. A previous study reported a heterogenous capability to
form 3D cultures between OS cell lines and noted that the SAOS-2 cells formed irregular
spheroids, whereas the MG63 formed more spherical spheroid [16]. Interestingly, from the
histology data in the paper the SAOS-2 spheroids displayed a compact cellular distribution.
However, the spheroids were significantly smaller (≤200 µm diameter) in comparison to
the aggregoid model reported here (~1 mm diameter). The histology data in this study
showed that a large area of apoptotic and necrotic activity within the SAOS-2 aggregoid
was present. This is likely impacting the stability of the aggregoids. As this has been
observed throughout the SAOS-2 samples, it is most likely due to the morphological nature
of the cell line. Nevertheless, phenotypical regions within the SAOS-2 model were still
observed and metabolite distributions were detected.
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Figure 1. Spatial segmentation of a HCC827, MG63 and SAOS-2 aggregoid from metabolite data by DESI-MSI. (a) Spatial
segmentation identified heterogeneous clustering phenotypes between aggregoid models. Segmentation of each sample
was performed independently and therefore the coloured clusters do not correspond between samples. (b) H&E stain of
same aggregoid sections from each model. Black dotted line highlights the approximate phenotypical regions identified by
segmentation clustering analysis. Scale bar 200 µm.
PCA was conducted to determine the differences between the three aggregoid models.
From the analysis, an obvious separation between the cell lines was observed with relatively
tight 95% confidence grouping (Figure 2). The distribution of the OS models within the
scores plot suggested more similarities in the metabolites compared to the lung model.
However, from the PLS-DA, there was clear variance in the detected metabolites between
the MG63 and SAOS-2 aggregoid models (Figure 3). This is as expected, as the fibroblastic
MG63 and epithelial SAOS-2 cell types will exhibit different metabolic behaviour. A
summary of the key metabolites identified in the aggregoid models is reported in Table 1.
A significant number of metabolites including fatty acids and lipids were detected and are
discussed.
Figure 2. PCA scores and loadings plot show separation of the MG63 and SAOS-2 aggregoid models from the HCC827
aggregoid model. Principal components, PC 1 (51.8%) and PC 2 (33.6%) showed the best separation between sample groups.
The discriminatory m/z values of interest were distributed separately from the cluster of peaks. Samples were grouped
with 95% confidence, HCC827 (red), MG63 (green), and SAOS-2 (blue).
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Figure 3. PLS-DA scores and loadings plot show variance between MG63 aggregoid model and the SAOS-2 aggregoid
model. Component 1 (69.6%) and component 2 (13.7%) showed the best separation between samples. The discriminatory
m/z values of interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence,
MG63 (green) and SAOS-2 (blue).
From the observed metabolites, differences in the detection levels across the tumour
aggregoid models were observed. In particular, ceramide species Cer 32:1; O2, Cer 34:1;
O2, and their chlorine adducts were significantly elevated in the SAOS-2 model (Table 1).
From the image, the intensity of Cer 34:1; O2 [M + Cl]− at m/z 572.480 was localised
across the aggregoid with concentrated levels within the core (Figure 4a). Some detection
was observed in the MG63 aggregoid, and even less so in the HCC827 model. Within the
MG63 aggregoid models, glycerophospholipid species, including phosphatidylcholine
(PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinosi-
tol (PI) were expressed considerably higher in comparison to the SAOS-2 and HCC827
models (Table 1).
Figure 4. Distribution of metabolites significantly detected in OS aggregoid models. Ion density maps of metabolites
outlining the core and outer area on the image. Mean intensity plotted on bar graph against the SAOS-2, MG63 and HCC827
aggregoids. Data is mean ± SD (n = 3), one-way ANOVA with Tukey post hoc test * p < 0.05, *** p < 0.001. Scale bar 200 µm.
Peaks identified (a) m/z 572.480, Cer 34:1; O2 [M + Cl]−; (b) m/z 885.549, PI 38:4.
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Table 1. Assignments and errors for metabolites detected in specific aggregoid models. Metabolites
were filtered by removal of isotope peaks and mass accuracy (<7 ppm). Significant metabolite
detection between tumour models was determined by mean intensities. Data is mean (n = 3),
one-way ANOVA with Tukey post hoc test * p < 0.05, ** p < 0.01, *** p < 0.001.
Metabolite m/z (Measured) Accuracy (ppm Error) Aggregoid
FA 8:1; O2 173.082 0.0 OS: SAOS-2 *
FA 9:1; O2 187.098 0.0 All
FA 11:1; O 199.136 0.0 All
FA 17:1 267.232 0.0 All: HCC827 *
FA 18:5 273.186 1.0 All
FA 18:3 277.217 −0.4 OS
FA 18:2 279.235 6.3 All: OS
FA 18:1 281.248 −0.4 All: HCC827 *
FA 18:2; O 295.229 3.4 All: HCC827 *
FA 20:5 301.218 0.0 All: MG63 *
FA 20:4 303.231 −0.2 All: MG63 *
FOH 27:0 395.427 3.3 MG63 *
FA 20:4 457.371 5.0 SAOS-2 **
Cer 32:1; O2 508.474 1.1 SAOS-2 ***
FAHFA 34:2; O 535.472 −0.9 All: HCC827 *
Cer 34:1; O2 536.506 1.9 SAOS-2 ***
Cer 32:1; O2 [M + Cl]− 544.449 −3.2 OS: SAOS-2 ***
FAHFA 36:2; O 563.504 −1.0 All: HCC827 ***
Cer 34:1; O2 [M + Cl]− 572.480 −2.2 OS: SAOS-2 ***
PI 18:0 599.320 −0.2 MG63 *
PE O-28:1 618.450 −1.0 SAOS-2 **
PE O-30:1 646.482 −0.3 SAOS-2 ***
PE O-34:2 700.527 −2.1 OS: MG63 ***
PE 34:1 716.524 0.1 OS: MG63 *
PE O-36:6 720.498 1.1 MG63 **
PE O-36:2 728.562 2.5 OS ***
PC O-33:1 730.577 1.7 OS: SAOS-2 *
PS O-33:0 734.533 −1.2 MG63
PC 33:2 742.540 1.4 MG63 **
PG 34:1 747.516 −3.0 OS: MG63 *
PE O-38:5 750.544 −0.3 MG63 *
PS 34:1 760.518 7.0 OS *
PE O-38:6; O 764.526 2.7 MG63 **
PS 36:1 788.544 −0.4 OS: MG63 **
PS 38:4 810.530 1.3 MG63 **
PG 40:7 819.519 0.7 MG63 **
PS 40:6 834.523 −6.3 OS *
PI 38:4 885.549 −0.9 OS: MG63 *
2.1.2. Comparison of OS Aggregoid Models with OS Human Tissue
The metabolic data obtained from the OS human tissue samples was spatially seg-
mented to classify the clusters with specific phenotypic regions. The spatial segmentation
analysis showed complex clustering patterns within all tissue sections in comparison to
the aggregoid models. This is due to the heterogeneity of the tissues comprising of many
cell types that form the tumorous tissue in addition to bone and cartilage. Figure 5a shows
the spatial segmentation of a tissue section from OS patient_826 imaged by DESI-MSI
and the histology stain after analysis (whole H&E image Figure 5b and enlarged regions
Figure 5c–f). From the pathology report, it was determined that the specific sample had can-
cerous tumour regions identified throughout the tissue and the osteoid bone was formed
by tumour cells. Therefore, detection of different tumorous phenotypes throughout the
whole tissue section was expected. From the segmentation analysis, a solid tumour region
(yellow cluster) with an osteoid bone island (purple/blue clusters) was identified on the
right of the tissue (Figure 5c). Similarities to this yellow tumour cluster were also detected
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throughout the sample (Figure 5d). A large area of mineralised bone within tumorous
tissue was also detected and determined by the sage green cluster (Figure 5d,e). In addition,
a significant area of dense osteoid bone with a filagree pattern was focally present and
outlined by purple/blue clusters (Figure 5f).
Figure 5. Spatial segmentation analysis of OS patient_826 tissue sample from metabolite data by DESI-MSI. (a) spatial
segmentation of OS section highlighting heterogeneous clusters throughout tissue. Scale bar 600 µm. (b) H&E of same
OS tissue section after image analysis. Scale bar 600 µm. Magnification of ROIs: (c) solid tumour (corresponding to the
yellow cluster) with osteoid island (corresponding to the purple/blue clusters) at the right of the tissue; (d) region of tumour
and mineralised bone located to the left of tissue (corresponding to the yellow and sage green clusters); (e) tumour and
mineralised bone located at the top of the tissue (corresponding to the sage green cluster); (f) Dense osteoid bone present
focally (purple/blue cluster). Scale bar 300 µm.
Figure 6 shows the spatial segmentation analysis of a tissue section from OS pa-
tient_882 and the histological image. From the pathology report, typical osteoblastic
osteosarcoma phenotypes were detected. Regions of lamellar bone were identified, the
medullary space contained various cell types with irregular nuclei, and osteoid production
by atypical mitotic cells was determined. From the DESI data, the different phenotypes
could be identified by the segmentation analysis. A large region of solid tumour was
identified on the right of the tissue (orange cluster) (corresponding enlarged H&E image
Figure 6c). The medullary space (blue cluster) with osteoid regions (green cluster) was lo-
calised within the focal region of the tissue (corresponding enlarged H&E image Figure 6d).
A region of lamellar bone (sage green) and a large area of osteoid formation were localised
within the left of the tissue (corresponding enlarged H&E image Figure 6e). It is noted
that the segmentation analysis was performed independently for each patient sample and
therefore the colour clusters do not correspond between groups. The segmentation analysis
is based on the metabolite distribution, some areas of sample that show no tissue present
on the histology images may show segmentation clusters due to the weak denoising of
the image. Therefore, the segmentation analysis here gives a generalization of the area in
complicated tissues such as the OS human patient samples.
PCA was performed to determine the similarities and variances between the two OS
aggregoid models with the two OS human tissue samples. It is stressed that the aggre-
goid data were acquired independently from the patient samples. Therefore, an indirect
comparison has been performed in this study and thus the results are of a preliminary
nature only. From the PCA scores plot, a clear separation of the aggregoid models from
the OS human tissue samples was observed (Figure 7). As the human tissue is comprised
of many heterogeneous regions and contains different cell types it was expected to have
variance from the single-cell type aggregoid models. In addition, slight separation of the
95% confidence grouping of the two patient samples is also likely due to the heterogeneity
between the tumour tissues. The MG63 aggregoid samples were relatively widely dis-
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tributed which suggests some variability within the group, which could be due to slight
culturing variation between replicates. For each remaining sample type however, tight
clustering between the samples was observed. A summary of the key metabolites within
the OS patient samples and the OS aggregoid models is reported in Table 2. The significant
metabolites detected within the samples highlighted the similarities that exist between the
OS aggregoid models and the OS human tissue.
Figure 6. Spatial segmentation analysis of OS patient_882 tissue sample from metabolite data by DESI-MSI. (a) spatial
segmentation of OS section highlighting heterogeneous clusters throughout tissue. Scale bar 800 µm. (b) H&E of same OS
tissue section after image analysis. Scale bar 800 µm. Magnification of ROIs in H&E image: (c) solid tumour (corresponding
to the orange cluster) at the right of the tissue; (d) region of medullary space with osteoid bone located focally (corresponding
to the green and blue clusters); (e) lamellar bone located at the left of the tissue (corresponding to the sage green cluster).
Scale bar 200 µm.
Figure 7. PCA scores and loadings plot show separation of the OS aggregoid models from the OS human tissue samples.
Principle components, PC 1 (48.6%) and PC 2 (22.4%) showed the best separation between sample groups. The discriminatory
m/z values of interest were distributed separately from the cluster of peaks. Samples were grouped with 95% confidence,
MG63 (green), and SAOS-2 (blue), OS patient_826 (red) and OS patient_882 (light blue).
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Table 2. Assignments and errors for metabolites detected in both the OS human tissue samples and OS aggregoid models,
MG63 and SAOS-2. Metabolites were filtered by removal of isotope peaks and mass accuracy (<7 ppm). Significant
metabolite detection between tumour models was determined by mean intensities. Data are mean (n = 3), unpaired t test















FA 18:2 279.234 2.4 Both 279.235 6.3 Both
FA 18:1 281.247 −0.4 Both 281.248 – 0.4 Both
FA 18:2;O 295.229 2.9 OS_882 * 295.229 3.4 MG63 *
FA 18:1;O 297.242 −6.0 Both 297.242 – 5.9 MG63 *
FA 20:4 303.231 0.2 OS_826 *** 303.231 – 0.2 Both
FA 18:2;O2 311.224 3.5 OS_882 * 311.223 0.7 Both
Cer 32:1;O2 508.474 0.7 OS_826 ** 508.474 1.1 SAOS-2 ***
FAHFA 34:2;O 535.473 1.1 Both 535.472 –0.9 Both
Cer 34:1;O2 536.505 0.0 OS_826 *** 536.506 1.9 SAOS-2 ***
Cer 32:1;O2
[M + Cl]− 544.451 0.6 OS_826 ** 544.448 –3.2 SAOS-2 ***
FAHFA 36:2;O 563.505 0.1 Both 563.504 –1.0 Both
FAHFA 36:1;O 565.522 4.2 Both 565.522 2.9 Both
Cer 34:1;O2
[M + CI]− 572.484 4.2 OS_826 *** 572.480 –2.2 SAOS-2 ***
PE O-28:1 618.451 1.6 OS_826 ** 618.450 –1.0 SAOS-2 **
PE O-30:1 646.613 −2.1 OS_826 *** 646.615 1.0 Both
Cer 40:1;O2
[M + CI]− 656.578 3.5 OS_826 ** 656.576 0.2 Both
PA 36:3 701.514 3.0 Both 701.511 –1.0 Both
PE 34:1 716.524 0.3 OS_826 * 716.524 0.1 MG63 *
PE O-36:2 728.560 −0.4 OS_826 * 728.562 2.5 Both
PC O-33:1 730.575 −0.8 Both 730.577 1.7 SAOS-2 *
PC 33:2 742.539 0.1 OS_826 * 742.540 1.4 MG63 *
PG 34:1 747.517 −1.1 OS_826 ** 747.516 –3.0 MG63 *
PE O-38:5 750.542 −2.6 OS_826 * 750.544 –0.3 MG63 *
PE O-38:6;O 764.524 0.4 OS_826 * 764.526 2.7 MG63 **
PS 36:1 788.544 −1.3 OS_826 ** 788.544 –0.4 MG63 **
PS 38:4 810.528 −1.5 OS_826 ** 810.530 1.3 MG63 *
PS 40:4 838.559 −1.3 OS_826 ** 838.562 2.2 Both
PI 38:4 885.550 0.5 OS_826 ** 885.549 –0.9 MG63
The major similarities between the OS human tissue samples and the OS aggre-
goid models is the detection of fatty acid species, specifically related to the arachidonic
metabolism pathway. Figure 8a–c shows FA 18:2, e.g., linoleic acid at m/z 279.234, FA 18:1,
e.g., oleic acid at m/z 281.247 and FA 20:4, e.g., arachidonic acid at m/z 303.231 within
the OS human tissues (mean intensities included in Supplementary Figure S1a–c). The
localisations of the metabolites were concentrated around the solid tumour regions of the
OS human tissues and distributed throughout the similar tumorous areas as identified by
the clustering analysis. These species were also identified at high levels in SAOS-2 and
MG63 aggregoid models (Figure 8e,f and Supplementary Figure S1d,e). Within the SAOS-2
model, the metabolites were distributed more within the periphery, compared to the MG63
model where the species were heavily distributed throughout the section.
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Figure 8. Fatty acid detection within OS human tissue and OS aggregoid models. Ion density maps of metabolites in OS
patient_826 and OS patient_882. Scale bar 500 µm and 800 µm, respectively. Ion density maps of aggregoid models outlining
the core and outer area. Scale bar 200 µm. Peaks identified in human tissue (a) m/z 279.234, FA 18:2; (b) m/z 281.247, FA
18:1; (c) m/z 303.231, FA 20:4. Peaks identified in OS models (d) m/z 279.235, FA 18:2; (e) m/z 281.248, FA 18:1; (f) m/z
303.231, FA 20:4. Mean intensity bar graph for each included in Supplementary Figure S1.
The phospholipids PS 38:4 at m/z 810.528 and PI 34:4 at m/z 885.550, that were
detected within the MG63 aggregoid were also detected significantly higher within the
metastatic OS patient_826 tissues. Both species were observed within the large tumorous
regions identified by the yellow and sage green cluster of OS patient_826, as low amounts
of m/z 810.528 and m/z 885.550 were distributed in the orange tumour cluster of OS
patient_882 (Figure 9 and Supplementary Figure S2).
Figure 9. Phospholipid species detected within OS human tissue and OS aggregoid models. Ion
density maps of metabolites in OS patient_826 and OS patient_882. Scale bar 500 µm and 800 µm,
respectively. Ion density maps of aggregoid models outlining the core and outer area. Scale bar
200 µm. Peaks identified in human tissue (a) m/z 810.528, PS 38:4; (b) m/z 885.550, PI 38:4. Peaks
identified in OS models (c) m/z 810.530, PS 38:4; (d) m/z 885.549, PI 38:4. Mean intensity bar graph
for each included in Supplementary Figure S2.
The ceramide species that defined the SAOS-2 aggregoid model were significantly
expressed within the metastatic OS patient_826 tissues. Cer 34:1; O2 at m/z 536.505 and
its chlorine adduct at m/z 572.484 [M + Cl]− were localised within the tumorous regions
that corresponded mainly to the sage green cluster of OS patient_826 (Figure 10 and
Supplementary Figure S3).
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Figure 10. Ceramide species detected within OS human tissue and OS aggregoid models. Ion density
scheme 826. and OS patient_882. Scale bar: 500 µm and 800 µm, respectively. Ion density maps of
aggregoid models outlining the core and outer area. Scale bar: 200 µm. Peaks identified is human
tissue a) m/z 536.505, Cer 34:1; O2; (b) m/z 572.484, Cer 34:1; O2 [M + Cl]−. Peaks identified in OS
models (c) m/z 536.504, Cer 34:1; O2; (d) m/z 572.480, Cer 34:1; O2 [M + Cl]−. Mean intensity bar
graph for each included in Supplementary Figure S3.
2.2. Protein Localisations
To define the individual cellular organisation and tumour activity within the OS
aggregoid models, IMC analysis was employed to detect protein and protein modification
markers at 1 µm spatial resolution. Proteomic markers relevant to osteosarcoma were
selected to identify structural and functional components that influence cancer metabolism.
A generic marker for DNA was used initially to determine the tissue organisation by
identifying the nucleus in individual cells within the OS aggregoid models (Figure 11). The
differences between the two OS models are defined by the expression of tumour markers,
vimentin and collagen. Both structural components show similar co-localisations within
the aggregoid sections, yet only expressed within the outer region of the SAOS-2 model as
they are more detected across the MG63 aggregoid (Figure 11).
Figure 11. Representative IMC images of protein marker distributions within the OS aggregoid
models. Scale bar: 100 µm. DNA intercalator identified individual cells within the aggregoid
sections. Protein markers vimentin and collagen expressed identified structural components within
the aggregoid tissue.
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Markers Ki-67, phosphorylated S6 ribosomal protein (pS6) and Histone H3 (pHH3)
display differences in the proliferation and differentiation activity between the two OS
models (Figure 12). In the SAOS-2 model the expression of Ki-67 is localised within
the outer region of the aggregoid, as within the MG63 model the marker is detected
throughout the section. This was also observed with the higher expression of pS6 and
pHH3 within the outer region of the SAOS-2 aggregoid, yet the limited expression within
the MG63 aggregoid was randomly distributed. In addition, a proxy hypoxia marker
glucose transporter 1 (Glut1) was detected solely within the core of the SAOS-2 aggregoid
as the marker was more homogenously expressed across the MG63 aggregoid (Figure 12).
Interestingly the marker for phosphorylated N-myc downregulated gene 1 (pNDRG1)
showed significant differences between the two OS models, with high expression in the
MG63 aggregoid and no expression in the SAOS-2 aggregoid (Figure 12).
Figure 12. Representative IMC images of protein marker distributions highlight different tumour microenvironment
phenotypes within the OS aggregoid models. Scale bar: 100 µm. Protein markers expressed identified the proliferative and
hypoxic regions via Ki-67 and Glut1, respectively. Markers in response to DNA damage, pNDRG1 and γH2AX. Proliferative
and differentiating phenotypes observed by pS6 and pHH3 markers.
2.3. Elemental Compositions
The elemental analysis of the two OS aggregoid models conducted by LA-ICP-MSI,
shows similar tumour aggregoid microenvironment phenotypes of an outer annular rim
and inner core as previously observed [14]. Slight differences between the metal distri-
butions within the aggregoids were observable. Mg and Zn were co-localised and highly
expressed over a large area within the MG63 aggregoid compared to the SAOS-2 aggregoid,
which was localised in a thin outer rim (Figure 13). Alternatively, Cu was localised more
within the centre of both OS aggregoid models (Figure 13).
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Figure 13. Elemental compositions within the OS aggregoid models identified the tumour microenvironment regions. H&E
stain of serial sections of same aggregoid models imaged during LA-ICP-MSI analysis. Scale bar: 100 µm. Elemental maps
of 24Mg, 66Zn and 63Cu.
3. Discussion
3.1. OS Metabolite Phenotyping
The different ceramide expression across the models was not unexpected. Ceramides
are primarily associated with tumour suppressor activity by triggering anti-proliferative cel-
lular processes such as apoptosis and autophagy [17]. Activation of ceramides are typically
induced by cellular stresses such as hypoxia or anti-cancer drug signalling [18,19]. Equally,
ceramides have also been associated with cell differentiation and bone development. Hill
& Tumber [20] detected ceramides in osteoblasts and determined low levels promoted
cellular proliferation, as high levels induced apoptosis to promote bone reformation. From
the histology images, a large area of apoptotic bodies was identified in the SAOS-2 model.
Thus, the heterogenous ceramide levels within the SAOS-2 aggregoid could be an indicator
of apoptotic activity within an inner hypoxic region and cellular differentiation in an outer
proliferative zone (Figure 4a). Though, as the ceramide detection within the apoptotic
region of HCC827 aggregoids were significantly lower than the SAOS-2 model, it suggests
ceramides are more associated with osteoblast-like cells. The discriminatory levels of
ceramides between the OS models, however, implies these metabolites differentiate the
mature osteoblast phenotype of the SAOS-2 model from the MG63 immature osteoblasts.
In highly proliferating cancer cells, the phospholipid metabolism is altered to promote
processes involved in the synthesis of signalling molecules, energy production and the
formation of cellular membranes [21]. From the histology image, the MG63 aggregoid
displayed a high density of proliferative cells across the tissue and therefore could be
reason for the higher detection of such phospholipids. In addition, the role of some
specific phospholipids has also been associated with aggressive properties of malignant
cancer types [22]. The observation of metabolites PS 38:4 at m/z 810.530 and PI 38:4 at
m/z 885.549 were significant within the MG63 aggregoids, with some detection in the
SAOS-2 aggregoids; PI 38:4 in particular being localised within the periphery of the MG63
aggregoid (Figure 4b) can be rationalised. A previous study comparing the lipidomic
profiles of low and high metastatic breast cancer cell lines reported both PS 38:4 and PI 38:4
were markedly greater in the high metastatic cell type [23]. The presence of these lipids
could suggest the MG63 aggregoid is exhibiting an aggressive tumoral behaviour, that is if
the phospholipids have the same metastatic-promoting effects in OS as they do in breast
cancer.
When comparing the metabolite levels within the OS aggregoid models to the OS
clinical tissue, the arachidonic acid metabolism was significant (Figure 8). This pathway has
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been associated with cellular proliferation and differentiation, and the promotion of cancer
growth and survival via the cyclooxygenase (COX) pathway [24,25]. This correlates to the
observations made in the OS aggregoid models, where proliferative cells were localised
within the outer region of the SAOS-2 model, whereas from the histology of the MG63
model, proliferative cells were localised throughout the aggregoid. Therefore, this could
suggest the localisation of the fatty acids within the OS human tissue samples could be an
indication of highly proliferative activity within the solid tumour regions.
The comparison of the data obtained from the aggregoid models with the patient data
showed some marked trends. Interestingly, the two aggregoid models follow a similar
detection pattern of a lower FA 18:2, e.g., linoleic acid signal and elevated levels of FA 20:4,
e.g., arachidonic acid as OS patient_826 (Figure 8). In contrast, OS patient_882 had higher
intensities of FA 18:2. It has been reported that the metabolism of arachidonic acid is also
involved in the promotion of angiogenesis, cell invasion and metastasis by the lipoxygenase
(LOX) pathway [26]. From the pathology reports, a case of metastasis was reported from
OS patient_826 and not in OS patient_882. The observation of an upregulation of FA 20:4,
e.g., arachidonic acid, suggests the detection of a possible marker for metastatic potential,
primarily within the solid tumour regions of OS patient_826 tissues. In contrast, a higher
detection of FA 18:2 within OS patient_882 tissues indicated a slower metabolism to FA
20:4, and thus could identify a lower metastatic potential. The similar detection levels of
the fatty acids within the OS aggregoids to the metastatic patient tissue therefore implies
the tissue models could be exhibiting metastatic-like behaviour. In addition, the elevated
levels of FA 20:4 within the MG63 aggregoid further suggests the cell type forms a higher
metastatic-like or aggressive tumour model compared to the SAOS-2 aggregoid.
The phospholipids PS 38:4 at m/z 810.528 and PI 34:4 at m/z 885.550 detected signifi-
cantly in the MG63 aggregoid (discussed earlier) were also detected significantly higher
within the metastatic OS patient_826 tissues. The localisations of both species were ob-
served within the large tumorous regions identified by the yellow and sage green cluster
of OS patient_826, as low amounts of m/z 810.528 and m/z 885.550 were distributed in the
orange tumour cluster of OS patient_882 (Figure 9a,b). These specific metabolites could
therefore correlate to high metastatic-like activity within OS, as previously observed in
highly metastatic breast cancer [23]. This supports the idea of the MG63 aggregoid model
displaying a metastatic-like phenotype and demonstrates similarities to the OS patient_826
human tissue. On the other hand, the SAOS-2 samples expressed a lower signal for both
phospholipid species and therefore suggests comparisons to a lower metastatic grade OS
tissue, such as OS patient_882.
Conversely, the ceramide species that defined the SAOS-2 aggregoid model were
significantly expressed within the metastatic OS patient_826 tissues. Cer 34:1; O2 at m/z
536.505 and its chlorine adduct at m/z 572.484 [M + Cl]− were localised within the tu-
morous regions that corresponded mainly to the sage green cluster of OS patient_826
(Figure 10). As discussed, the segmentation analysis highlighted this ROI with tumorous
tissue and mineralised bone. The elevated ceramide levels within this region could be
indicative of cellular differentiation and osteoid formation within the human tissues [20].
The comparison to the SAOS-2 aggregoid thus suggests the model exhibits similarities
to regions in the OS tissue that express the mature differentiating osteoblast phenotype
that mediates bone mineralisation. This contrasts with the MG63 model, which is deter-
mined as an immature osteoblast phenotype and could be reason to the lack of ceramide
detection. Considering the differences in metabolic activity between the two OS aggregoid
models and the processes within OS human tissue, it demonstrates how the 3D models can
correspond to different phenotypes within the same tumour. This is significant in terms
of drug development, as both models can be used to predict the cellular response within
heterogeneous tissue.
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3.2. Protein Localisations Differ between OS Aggregoid Models
From the DNA expression (Figure 11), differences between the MG63 and SAOS-2
sections can be immediately defined. Within the MG63 model, the DNA marker showed
whole nuclei expressed homogenously throughout the section. When compared to the
SAOS-2 model, a more heterogenous pattern was observed whereby the outer region of
the aggregoid showed whole nuclei, as in the core the DNA was more condensed. This is a
known indicator of nuclear disassembly and apoptotic bodies [27], and implies a prevalent
necrotic region within the SAOS-2 aggregoid compared to the MG63. This observation was
consistent across OS aggregoid samples imaged with IMC and agreed with the metabolite
data.
A homogeneous distribution of vimentin and collagen was detected throughout the
MG63 aggregoid, as within the SAOS-2 aggregoid the protein markers were prominently
expressed within the outer region (Figure 11). Vimentin is known as a fibroblastic interme-
diate filament and a mesenchymal cell marker in differentiated cell types [10]. A higher
expression of vimentin across the MG63 aggregoid compared to the lower expression in the
periphery of the SAOS-2 aggregoid could be highlighting the differentiating mesenchymal
cells within the models. In addition, an increase in vimentin has been associated with the
overexpression of cyclooxygenase enzyme, COX-2 in MG63 cells [28]. COX-2 is involved in
the metabolism of arachidonic acid and promotes angiogenesis and migration. Therefore,
the vimentin expression complements the metabolite data discussed previously, where
significantly high levels of FA 20:4, i.e., arachidonic acid was localised across the MG63
aggregoids, and only observed in the periphery of the SAOS-2 aggregoids.
The localisation of collagen suggests a similar expression as vimentin. Collagen is
an important protein in bone when it is mineralised. The more differentiated the OS cells,
the more collagen that is produced. Therefore, the levels of collagen could associate with
tumour invasion by the nature of the differentiation status of the cells. The localisation of
collagen within the periphery of the SAOS-2 aggregoid indicates an area of differentiation
within the outer region, as the expression across the MG63 aggregoid suggests differentiated
cells are present throughout (Figure 11). One study reported a higher production of collagen
type I in SAOS-2 cells in comparison to MG63 cells [29]. The expression of collagen I has
also been associated with ALP activity during bone mineralisation [30], an activity that
has been detected high in SAOS-2 cells [4]. In contrast, MG63 cells were reported to
express higher levels of collagen III than collagen I [31]. Unfortunately, the marker used in
this study detected all types of collagen, and therefore the specific type expressed in the
aggregoid models was not determined. However, the presence of different collagen types
could have influenced the heterogeneity between the models.
Interestingly, the markers that defined the distinctive proliferative outer region and
hypoxic core phenotypes within the lung adenocarcinoma aggregoid [14] are expressed
differently between the two OS models. Similar to the HCC827 aggregoid, the SAOS-2
model showed the hypoxia marker, Glut1 localised within centre of the tissue surrounded
by an annular expression of the proliferative marker, Ki-67 (Figure 12). This validates the
presence of cellular proliferation and differentiation within the periphery of the SAOS-2
model and identifies the core as a region of hypoxia. In the MG63 aggregoid however, a
highly intense distribution of Glut1 with an expression of Ki-67 were both detected across
the tissue (Figure 12). The purpose of Glut1 is to provide energy through the transport
of glucose into cells that is converted into lactate for cancer to grow and survive in a
severe microenvironment, such as hypoxia. High levels of Glut1 are therefore heavily
associated with hypoxic tumours and has been correlated to metastatic outcome in some
patients [32]. In OS, it was reported that the Glut1 gene is overexpressed in correlation with
the hypoxia inducible factor (HIF)-1α to promote tumour progression and is predictive of
drug resistance and poor outcome in patients [33]. A higher Glut1 expression in MG63 cells
compared to SAOS-2 cells has been previously reported [34] and a knockdown of the Glut1
gene showed inhibition of MG63 cell growth [35]. From the imaging data, the expression
of Glut1 across the MG63 aggregoid suggests the gene is constantly switched on in all cells,
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regardless of the microenvironment. This in turn implies there is a constant stability of
HIF-1α, consistent with a hypoxic environment but irrespective of oxygen levels in the
MG63 model. This could give an indication of an aggressive hypoxic tumour model. This
may also explain the Ki-67 expression across the MG63 aggregoid, whereby the cells are
able to proliferate under severe hypoxic conditions due to high glucose concentrations
imported by the overexpressed Glut1.
The marker for phosphorylated N-myc downregulated gene 1 (pNDRG1) showed
significant differences between the two OS models, with high expression in the MG63
aggregoid and no expression in the SAOS-2 aggregoid (Figure 12). NDRG1 is a stress
responsive gene that can have both oncogenic and tumour suppressor roles involved in
cellular differentiation, tumour progression and metastasis, hypoxia and DNA damage
response [36–38]. It was reported an upregulation of NDRG1 was linked to an increase in
hypoxia and HIF-1α expression [39]. This could therefore explain the co-localisation of
pNDRG1 with Glut1 in the MG63 aggregoid, however no detection was observed in the core
of the SAOS-2 aggregoid. Interestingly, the detection of pNDRG1 in the SAOS-2 cell line
has been reported [40], however at significantly lower levels than in the MG63 cells. It was
thought the decrease in pNDRG1 in the SAOS-2 cells was due to the differentiation state of
the cells and the increased invasion potential. The group, however, noted the detection
of pNDRG1 had no effect on the invasive properties of MG63 cells and therefore the role
of pNDRG1 between the OS cell lines could be due to the differences in differentiation
and cell phenotypes. In this study, growing the cells in 3D could have downregulated the
NDRG1 gene, hence no detection of the protein marker, however without comparing the
expression to 2D cells this cannot be confirmed.
The distribution of pS6 (Figure 12) can be explained as follows. pS6 is an active
marker for mTOR signalling which induces cancer growth and is downregulated in the
presence of hypoxia [41]. A low expression of the pS6 marker in the MG63 cells is therefore
likely associated with the high levels of the Glut1 marker. The reverse expression of these
markers is observed in the SAOS-2 model. This is a similar explanation for the pHH3
marker expression which identifies cells undergoing mitosis [42].
3.3. Elemental Compositions Complement Protein Expression
The LA-ICP-MSI data (Figure 13) also throws up some interesting observations. Mg is
an essential component utilized in many cellular pathways and is particularly required
for the cell cycle [43]. Therefore, a lack of Mg can be an indicator non-proliferative activity.
From the IMC data, the Ki-67 proliferation marker showed the MG63 model expressed
proliferative cells across the tissue, as the SAOS-2 model displayed a distinctive outer
proliferative region. The elemental composition of Mg therefore correlated with the Ki-
67 expression. In addition to this, it has been reported that Mg ions can promote the
differentiation of mesenchymal stem cells to induce growth [44,45]. The elevated levels
within the aggregoids could therefore be indicative of the matrix differentiation process in
the mesenchymal cells across the tissue.
The absence of Zn in the core of the HCC827 aggregoid has been associated with the
activation of HIF-1α in hypoxia as excess Zn was shown to induce proteasomal degradation
of HIF-1α [46]. This theory coincides with the proliferative and hypoxic phenotype of
the SAOS-2 model. The high Glut1 expression across the whole MG63 aggregoid would
however disprove this, as elevated levels of Zn activity were detected. Alternatively,
Zn has been linked to vimentin production, whereby the ions influence the assembly of
vimentin in tissues [47]. Zn could therefore be highlighting the formation of the structural
component within the tissues due to the similar distributions of Zn and vimentin in the
MG63 and SAOS-2 models. This would also correlate to the association of Mg with matrix
differentiation in the mesenchymal cells.
The detection of Cu ions within the core of the aggregoid model could be due to
an upregulation of Cu-efflux transporter, ATP7A induced by the activation of HIF-1α in
hypoxia [48]. A large area of Cu was detected within the SAOS-2 model, this is likely
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due to the large hypoxic region as observed in the H&E stain of the serial section, and
in the Glut1 expression in the biological replicate from the IMC data. As for the MG63
H&E stain, it does show a small region of cells within the core that could be experiencing
cellular damage, however apoptotic bodies were not present. This would suggest the MG63
aggregoid core is a less dense area due to the natural gradient of nutrients and oxygen and
hence this is why Cu is accumulating within this region.
4. Materials and Methods
4.1. Materials
Alginic acid, CaCl2, casein solution, DPX mountant, eosin, EDTA, EtOH, haema-
toxylin, NaCl, paraformaldehyde (PFA), polyvinylpyrrolidone (PVP), sodium citrate, Tri-
ton™ X-100 and xylene substitute were purchased from Sigma-Aldrich (Gillingham, UK).
Hydroxypropyl-methylcellulose (HPMC) was purchased from Alfa Aesar (Thermo Fisher
Scientific, Heysham, UK).
4.1.1. 3D Cell Culture Growth
MG63 and SAOS-2 cell lines (ATCC) were independently cultured in alpha modified
Eagle’s medium (αMEM) (Lonza Ltd., Castleford, UK), and HCC827 cell line was cultured
in Dulbecco’s modified Eagle’s medium (DMEM). Media was supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin (Lonza Ltd., Manchester, UK). The
aggregated 3D cell culture models were generated based on the method of Palubeckaitė
et al. [13] and is described as follows: Cells were maintained at 37 ◦C, 5% CO2 and grown to
80% confluence prior to use. To generate the initial tumor spheres, cells were suspended in
1.2% (w/v) alginic acid (SigmaAldrich, Gillingham, UK) in 0.15 M NaCl at 1 × 106 cells/mL
and extruded out of a needle into 0.2 M CaCl2 to polymerise the alginate into beads. Beads
were washed with 0.15 M NaCl before culturing in DMEM media for 14 days to yield
spheroids ∼100 µm in diameter, and media was replaced every 72 h. Alginate beads
were dissolved in an alginate buffer (55 mM sodium citrate, 30 mM EDTA, 0.15 M NaCl)
to release spheroids into solution. Spheroids were washed with PBS (Lonza, Castleford,
UK) before seeding spheroids into 1% agarose-coated 96-well plate in growth medium.
Spheroids were cultured for 7 days to form aggregoids of an approximate 1 mm diameter
before harvesting. Spheroid and aggregoid development were analyzed by fluorescent
staining with Hoechst 33,342 and propidium iodide staining (10 µg/mL each) for 30 min.
Fluorescent images were obtained using the Olympus IX81 Microscope (Southend-on-Sea,
UK) and images were captured using CellˆF Multifluorescence and Imaging Software
(Europa Science Ltd., Cambridge, UK)
4.1.2. Aggregoid Preparation
Aggregoids were prepared for imaging analysis based on the tissue embedding proto-
col previously reported [49]. Briefly, aggregoids were washed in PBS prior to embedding
in media made of 7.5% HPMC and 2.5% PVP. Embedded tissues were flash frozen in
liquid nitrogen and stored at −80 ◦C. Frozen aggregoids were sectioned at 10 µm thickness
using a Leica CM3050 cryostat (Leica Microsystems, Milton Keynes, UK) operating at
−18 ◦C. Sections were thaw-mounted onto polylysine glass slides followed by immediate
desiccation with N2 and subsequent vacuum packing for storage at −80 ◦C [50].
4.1.3. Tissue Sample Collection and Handling
Two samples of human bone tissue biopsies which had been previously classified by
conventional pathology as osteoblastic osteosarcoma were obtained from the Children’s
Cancer and Leukemia Group Tissue Bank. The samples were provided following ethical
approval of this study (Project Reference 2017 BS 06). Samples were snap frozen and
cryosectioned on a CM1950 cryostat (Leica Biosystems, Milton Keynes, UK). Sections were
cut at 10 µm thickness and n = 3 sections of each sample from different depths of the tissues
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were thaw mounted onto positively charged X-tra® adhesive slides (Leica Biosystems,
U.K.).
4.1.4. Small Molecule Analysis
Metabolite and lipid images were obtained by DESI-MSI on a Thermo Fisher Q-
Exactive mass spectrometer (Thermo Fisher Inc., Offenbach, Germany) at 40 µm spatial
resolution as reported in Chapter 2.3.5.3. One technical repeat was acquired with n = 3
biological repeats. The DESI-MSI data were analysed by SCiLS™ Lab MVS Premium 3D
version 2020a (Bruker Daltonics, Bremen, Germany) RMS normalization. Metabolites and
biological pathways were identified by METASPACE (https://metaspace2020.eu, accessed
on 6 July 2021). The peak list from each aggregoid section was exported into csv files and
grouped together. The data was then imported into MetaboAnalyst 5.0 [51] to conduct
multivariate analysis. PCA and PLS-DA were performed on the selected sample groups for
each aggregoid model. The samples were normalised by the median, before applying log
transformation and Pareto scaling on the data. The data was displayed in scores plots with
95% confidence regions to determine variance between groups. Loadings plots displayed
the m/z values that profiled specific groups. The ion abundances for the m/z values were
generated into histograms for comparison between regions using GraphPad™ Prism®
software (La Jolla, CA, USA).
4.1.5. IMC Analysis
Tissues were fixed with 4% PFA for 10 min at RT. Prior to staining, tissues were
permeabilized with 1× casein solution containing 0.1% Triton™ X-100 (5 min) at RT.
Tissues were then incubated with blocking buffer (1× casein solution) for 30 min at RT. An
antibody cocktail (Supplementary Table S1) was made containing the appropriate dilutions
for the antibodies. Tissues were incubated with the antibody cocktail overnight at 4 ◦C.
DNA Ir-Intercalator (Fluidigm®) was diluted 1:400 and applied to tissues for 30 min at
RT. Washes with PBS were performed three times between each step, with the last step
washed in deionized water for 30 s. Slides were left to air dry until analysis. Images were
acquired on the Hyperion Imaging System (Fluidigm®) with the laser tuned to fully ablate
the tissue. One technical repeat was acquired with n = 1 biological repeat. The imaging
data was analysed using the MCD Viewer v1.0.560.2 software (Fluidgim®).
4.1.6. Elemental Analysis
Experiments were conducted using a NexION 350X ICPMS (Perkin Elmer, Waltham,
MA, USA) coupled to an UP-213 LA system (New Wave Research, Fremont, CA, USA)
with a frequency quintupled 213 nm Nd: YAG laser. Laser parameters were optimised
to 6 µm spot size with laser power 46%, 25 µm/s scan speed, 0.07 J cm−2 laser fluence,
and 20 Hz repetition rate. The sample was ablated line by line with 6 µm raster spacing
at 1.31 min acquisition time. For the ICP-MS instrument there was a direct flow with a
rate of 1.4 L/min. The following settings were used in standard mode with an 18 L/min
plasma gas flow, 1.2 L/min auxiliary gas flow at 1600 W RF power. Isotopes monitored
included 24Mg, 66Zn and 63Cu and the instrument was controlled using Syngistix software.
One technical repeat was acquired with n = 1 biological repeat. Data analysis was achieved
using Iolite Software on Igor Pro (WaveMetrics, Tigard, OR, USA).
4.1.7. Histology Analysis
After DESI-MSI, aggregoid sections were stained using Mayer’s haematoxylin and
eosin solutions. Sections were fixed in 4% PFA (10 min) before staining with haematoxylin
(1 min). Tissues were rinsed in tap water before and after submerging in acid alcohol.
Tissues were subsequently stained with eosin for 30 s prior to washing tap water, then
subsequently washed in 3× absolute EtOH (1 min). Finally, tissues were submerged in
xylene substitute (1 min) twice and mounted using DPX mountant. Stained tissues were
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imaged with Aperio CS2 digital pathology scanner (Aperio Tech., Oxford, UK) at 40× and
visualized with ImageScope software (Aperio Tech.).
5. Conclusions
In this study, a multimodal imaging methodology was employed to characterise two
models of osteosarcoma for the purposes of a pre-clinical in vitro tool. Firstly, in-depth
phenotyping of the metabolite activity within the two OS aggregoid models was achieved.
A comparison of the metabolite data with OS human tissue samples revealed relevant fatty
acid and phospholipid markers. Although, annotations of these species require MS/MS
analysis for confident identification of the metabolites. From the putative assignments
however, it was suggested that the MG63 aggregoids displayed an aggressive tumour
model that exhibited metastatic-like potential. Alternatively, the SAOS-2 aggregoids are
the more mature osteoblast-like phenotype that expressed characteristics of cellular differ-
entiation and bone development. It was determined the two OS aggregoid models shared
similarities of metabolic behaviour with different regions of OS human tissues, specifically
of the higher metastatic grade. This is significant in terms of therapeutic research and
development to target against aggressive in vivo OS tumours.
In addition, employing IMC showed significant differences in the distribution of
protein markers within the OS aggregoid models. The SAOS-2 aggregoid displayed a
typical tumour microenvironment with an inner hypoxic core (Glut1 marker) and an outer
proliferative region (Ki-67 marker). Interestingly, the MG63 aggregoid protein expression
distributions did not show the presence of such distinct regions. Furthermore, the elemental
compositions within the aggregoid models corresponded to the protein distributions of
proliferative activity and formation of structural components. The complementary nature of
both the IMC and LA-ICP-MSI data confirmed the heterogeneity of metabolite distributions
between the 3D models.
Overall, multimodal MSI determined the unique characteristics of two OS aggregoid
models and improved the understanding of complex tumour microenvironments. MSI anal-
ysis of aggregoid models demonstrated a potential methodology to facilitate pre-clinical
applications of cancer research and drug development for improved patient outcome.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/metabo11080506/s1, Figure S1: Mean intensity plotted on bar graph of fatty acid detection
within OS human tissue and OS aggregoid models, Figure S2: Mean intensity plotted on bar graph of
metastasis-related phospholipid species within OS human tissue and OS aggregoid models, Figure
S3: Mean intensity plotted on bar graph of ceramide species detected within OS human tissue and OS
aggregoid models, Table S1: Protein and protein modification markers and the respective antibodies
used.
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